Medtronic (MDT) Stock
Global medical device leader with diverse portfolio. Here's the price, business snapshot, and what's worth knowing about Medtronic in July 2026.
Medtronic PLC (MDT) is a leading global medical-technology company that designs, manufactures and sells a wide range of devices and therapies across cardiac, vascular, diabetes, neurological and spinal markets. Its portfolio includes pacemakers, insulin pumps, neurostimulation systems, spinal implants and surgical tools, generating a mix of implanted-device revenue and recurring consumables. With a market capitalisation of about $122.91bn, Medtronic benefits from ageing populations, steady demand for long-lived devices and an ongoing pipeline of incremental innovations. Important investor considerations include regulatory scrutiny, reimbursement and pricing pressures, competition from peers and emerging entrants, and occasional litigation. The company has historically returned cash through dividends and buybacks, but future payouts depend on cash flow and strategic priorities. This overview is general educational information only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future results.
Why It’s Moving
Medtronic is moving mostly on steady analyst optimism as investors wait for a fresh catalyst.
- Analyst sentiment remains broadly positive, with consensus around a Buy or Moderate Buy, suggesting Wall Street still sees room for Medtronic despite limited near-term catalysts.
- Recent analyst updates continue to cluster near the low-$100s price-target range, reinforcing the view that the stock’s valuation is being driven more by expectations for steady execution than by a fresh company-specific shock.
- The lack of major new earnings or company headlines in the past week means MDT is trading more on the broader healthcare-device backdrop, where investors are focused on margin discipline, procedure volumes, and whether growth can re-accelerate.
Medtronic is moving mostly on steady analyst optimism as investors wait for a fresh catalyst.
- Analyst sentiment remains broadly positive, with consensus around a Buy or Moderate Buy, suggesting Wall Street still sees room for Medtronic despite limited near-term catalysts.
- Recent analyst updates continue to cluster near the low-$100s price-target range, reinforcing the view that the stock’s valuation is being driven more by expectations for steady execution than by a fresh company-specific shock.
- The lack of major new earnings or company headlines in the past week means MDT is trading more on the broader healthcare-device backdrop, where investors are focused on margin discipline, procedure volumes, and whether growth can re-accelerate.
When is the next earnings date for MEDTRONIC PLC (MDT)?
Medtronic’s next earnings date is not yet officially confirmed, but it is most commonly estimated for August 18, 2026. That report would cover fiscal Q1 2027. Some sources place the announcement in the August 20–21, 2026 window, so the date may shift slightly based on the company’s final schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Medtronic's stock with a target price of $93.59, suggesting significant growth potential.
Financial Health
Medtronic is performing well with strong revenue and profits, indicating healthy business operations.
Dividend
Medtronic's dividend yield of 3.5% provides a reasonable return for investors seeking regular income. If you invested $1000, you would be paid $28.40 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring MDT
Boston Scientific Penumbra Deal (Cardiovascular M&A)
Boston Scientific is set to acquire Penumbra for $14.5 billion, marking a significant expansion into the high-growth thrombectomy and neurovascular device markets. This major consolidation could catalyze further M&A activity, creating investment opportunities among other innovative companies in the cardiovascular sector.
Published: 17 January 2026
Explore BasketGlobal Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Published: 12 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketMedTech Stocks: Brazil Market Risks & Opportunities
Brazil's growing demand for advanced healthcare presents an opportunity to modernize its medical infrastructure and improve patient outcomes. This basket offers exposure to the leading US and European companies supplying Brazil with robotic surgery systems, AI diagnostics, and innovative medical devices.
Published: 21 October 2025
Explore BasketHealthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: 14 October 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: 23 September 2025
Explore BasketHealthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: 22 September 2025
Explore BasketJohnson & Johnson (Healthcare Diversification)
As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.
Published: 16 September 2025
Explore BasketARK Innovation ETF: What's Next for Africa's Growth?
Africa's digital economy is rapidly expanding, creating demand for cutting-edge technologies in finance, healthcare, and energy. This basket offers potential exposure to US-listed companies leading the disruptive innovation trends that are shaping the continent's future.
Published: 15 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady implant demand
Implanted devices and related consumables can provide recurring revenue as populations age, though demand and pricing may vary across markets.
Global market reach
Sales span developed and emerging markets, offering diversification but exposing the company to currency and local reimbursement risks.
R&D-driven pipeline
Ongoing product development and approvals can drive long-term growth, although clinical outcomes and commercial uptake are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
